National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 2 of 1997)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, was introduced to establish a framework for the provision of health services and the administration of national health programs, including the Pharmaceutical Benefits Scheme (PBS). This legislation was pivotal in addressing the need for a coordinated approach to managing healthcare costs and ensuring access to essential medications for the Australian population. The policy objective underpinning the Act is to provide affordable and accessible healthcare services to all Australians, with a particular focus on the equitable distribution of pharmaceutical benefits. The legislative instrument in question, F2008B00071, pertains to a declaration made under the Act, which specifies certain drugs and medicinal preparations that will no longer be subject to the provisions of Part VII of the Act, effective from 1 February 1997. This instrument was issued by David Trevor Graham, the Assistant Secretary of the Pharmaceutical Benefits Branch within the Department of Health and Family Services, acting as the delegate for the Minister for Health and Family Services, following consultation with the Pharmaceutical Benefits Advisory Committee.

Scope and Application

The National Health Act 1953, through this legislative instrument, applies to specific drugs and medicinal preparations listed in the Schedule, effectively removing them from the Pharmaceutical Benefits Scheme (PBS). This legislative instrument specifies that from 1 February 1997, the drugs and preparations including Benzathine Penicillin with Procaine Penicillin and Benzylpenicillin Potassium, among others, are no longer subject to the provisions of Part VII of the National Health Act 1953, which governs the PBS. The declaration was made by the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Family Services, acting as the delegate of the Minister for Health and Family Services, following advice from the Pharmaceutical Benefits Advisory Committee. The removal from the PBS impacts the availability of these drugs under the scheme and the costs borne by patients, thereby affecting pharmaceutical entities and consumers directly involved in the procurement and use of these medications. The changes are applicable nationally, aligning with the federal jurisdiction of the Commonwealth of Australia.

Key Provisions

The key operative sections of this legislative instrument pertain to the cessation of certain drugs and medicinal preparations from being subject to Part VII of the National Health Act 1953 (sections 1 and 2). This means that the specified substances listed in the Schedule will no longer be covered by the Pharmaceutical Benefits Scheme (PBS) as of 1 February 1997. These drugs and preparations, including Benzathine Penicillin with Procaine Penicillin, Benzylpenicillin Potassium, Bifonazole, Clotrimazole, Econazole Nitrate, Ergometrine Maleate, Miconazole Nitrate, Sulfamethizole, Lemon Syrup B.P., Siberian Fir Oil B.P.C. 1949, and Wool Alcohols B.P., are explicitly removed from the PBS. The Act imposes obligations on the entities and individuals it governs by mandating that the Assistant Secretary, Pharmaceutical Benefits Branch, in consultation with the Pharmaceutical Benefits Advisory Committee, makes the declaration under subsection 85(2AA) of the National Health Act 1953. The Assistant Secretary, David Trevor Graham, acting as the delegate of the Minister for Health and Family Services, has obtained the necessary advice and issued the declaration accordingly. The Schedule lists the specific drugs and preparations that will no longer be covered by the PBS, thereby formalising the removal from the scheme. The legislation does not explicitly state any offences, penalties, or civil/criminal consequences for breach in relation to the removal of these drugs from the PBS. However, it is essential to note that any breach of the terms outlined in the National Health Act 1953 or related regulations could potentially lead to legal consequences. For example, if entities or individuals continue to claim benefits for these drugs after the effective date, they might face penalties under the broader provisions of the Act or other related legislation. The precise penalties would depend on the specific nature of the breach and the relevant provisions of other applicable laws.